White Collar Defense
Kirk Ogrosky defends corporations and individuals in government investigations, qui tam litigation, and trials. An experienced litigator and trial lawyer, he has first-chaired numerous federal cases with juries reaching verdicts in his favor on all counts over the last 10 years.
Kirk joined the firm in 2010 after a distinguished career in government. He served as deputy chief of the Fraud Section in the Criminal Division of the US Department of Justice from 2006 to 2010. Because of his work in that role, Kirk is widely recognized as the key architect behind modern criminal healthcare enforcement programs. In 2006, he created the Medicare Fraud Strike Force in partnership with HHS-OIG and FBI. He managed teams of prosecutors handling national healthcare, FCPA, and securities fraud cases. Prior to DOJ, he was an Assistant US Attorney in the Southern District of Florida and an Assistant Attorney General in Kentucky.
Ranked as a leading lawyer by Chambers USA, clients praised Kirk’s “exceptional work” and “great judgment.” In 2014 and 2015, Kirk was designated as one of Washington's Top-100 lawyers by Super Lawyers. He has been described by his peers as "one of the premier healthcare experts in the United States.” Other recognition includes Washingtonian’s Best Lawyers for healthcare, LMG’s Life Sciences Star, Super Lawyers for white collar defense, and the highest rating by Martindale (AV).
Kirk speaks as a faculty member, panelist and keynote on healthcare fraud, foreign bribery, criminal law enforcement, and trial issues. He serves as an adjunct professor of law at Georgetown University where he teaches healthcare fraud.
White Collar Defense Representative Matters
- Physicians and individuals in litigation involving healthcare fraud offenses.
- Healthcare providers and physicians in government investigations and qui tam cases involving alleged health care fraud, Anti-Kickback Statute, and Stark law violations.
- Pharmaceutical manufacturers in qui tam cases related to alleged violations of the FDCA and Anti-Kickback Statute violations.
- Pharmaceutical and device manufacturers and senior executives in FCPA and UK Bribery Act investigations.
- Litigated False Claims Act cases involving allegations related to (a) hospital and provider billing of drugs and devices; (b) cost report fraud; (c) improper rebating; and (d) miscoding of patient transfers, among others.
The Legal 500 US 2014-2015 for White-Collar Criminal Defense
US Attorney General's Award for Distinguished Service, 2008.
US Assistant Attorney General's Award for Special Initiative, 2007.
HHS OIG's Exceptional Achievement and Prosecutive Leadership Awards, 2010.
EOUSA Director's Award for Superior Performance as an Assistant US Attorney, 2003.
HHS OIG's Integrity and Cooperative Achievement Awards, 2008.
Chambers USA: America's Leading Lawyers for Business 2012-2015 for Healthcare (DC)
Washington, DC Super Lawyers 2012-2014 for Criminal Defense: White Collar and Healthcare
Washingtonian's "Best Lawyers" 2013 for Health Care Law
LMG Guide, Life Sciences Star 2012-2015
"Health Care Fraud in America: Honest Providers Struggle with Enforcement While Criminals Go Free
" ABA's Criminal Justice Magazine (Featured Cover Article), Vol. 30, No. 1,
"Global Corruption Enforcement: Protecting Corporate Interests (Part 1 of 2)
" Business Crimes Bulletin, Volume 22, No. 3,
"Developments Impacting the Investigation, Enforcement, and Defense of White Collar Criminal Activity in Healthcare
" Managing White Collar Legal Issues (Inside the Minds) Ch. 3,
"Int'l Anti-Bribery Enforcement in Pharmaceutical Industry
" European Healthcare Compliance Programme, Sciences Po, Paris, France, June 2015
"Anti-Kickback and Stark Developments, Physician Arrangements and Compliance Practices
" ABA 25th Annual Healthcare Fraud Institute (Planning Committee), Miami, Florida, May 2015
"Healthcare Enforcement in 2015
" AHA-PhRMA-AdvaMed Compliance Officers’ Conference, AHA Sponsored Dinner Speaker, Ethicon, New Jersey, April 2015
"Quality of Care & Medical Necessity Cases and Investigations
" Health Care Compliance Association, National Compliance Institute, Orlando, Florida, April 2015
"Stark: The Regulation of Physician Referrals
" 15th Annual Conference of Emerging Issues in Healthcare Law, ABA, Phoenix, AZ, March 2014
"Anti-Corruption Enforcement Focus by US DOJ in Pharmaceutical Industry
" Asia Pacific Pharmaceutical Compliance Congress, Kuala Lumpur, Malaysia, September 2013
"Qui Tam Practice Insights
" 13th Annual Pharmaceutical Regulatory and Compliance Congress, Washington, DC, November 2012
"Federal Fraud Enforcement In the Business of Health Insurance after ACA
" National Association of Insurance Commissioners (NAIC) Annual Convention, Washington, DC, November 2011
"Off-Label Enforcement Activities in 2010
" CBI's 12th Annual Guidelines for Disseminating Off-Label Information, Washington, DC, October 2010
"Negotiating and Resolving Healthcare Fraud Cases with the Government
" ACI's Government Investigations for Life Sciences (Conference Co-Chair), Philadelphia, PA, September 2010
FCPA News and Insights
" (PDF: 7.62 MB) Aug 2015
FCPA News and Insights
" (PDF: 7.68 MB) Feb 2015
FCPA News and Insights
" (PDF: 4.42 MB) Aug 2014